Literature DB >> 17786187

Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis.

Natacha Entz-Werle1, Thomas Lavaux, Nadia Metzger, Corinne Stoetzel, Christelle Lasthaus, Perrine Marec, Chantal Kalifa, Laurence Brugieres, Hélène Pacquement, Claudine Schmitt, Marie-Dominique Tabone, Jean-Claude Gentet, Patrick Lutz, Annie Babin, Pierre Oudet, Marie Pierre Gaub, Fabienne Perrin-Schmitt.   

Abstract

Dysregulated cell growth or differentiation due to misexpression of developmental critical factors seems to be a decisive event in oncogenesis. As osteosarcomas are histologically defined by malignant osteoblasts producing an osteoid component, we prospected in pediatric osteosarcomas treated with OS94 protocol the genomic status of several genes implied in ossification processes. In 91 osteosarcoma cases, we focused on the analysis of the fibroblast growth factor receptors (FGFRs) TWIST, APC, and MET by allelotyping, real-time quantitative polymerase chain reaction, gene sequencing, and protein polymorphism study. Our study supports the frequent role of TWIST, APC, and MET as osteosarcoma markers (50%, 62%, and 50%, respectively). TWIST and MET were mainly found to be deleted, and no additional APC mutation was identified. Surprisingly, FGFRs are abnormal in only < 30%. Most of these factors and their abnormalities seem to be linked more or less to one clinical subgroup, but the most significant correlation is the link of MET, TWIST, and APC abnormalities to a worse outcome and their combination within abnormal tumors. A wider cohort is mandatory to define more robust molecular conclusions, but these results are to be considered as the beginning of a more accurate basis for diagnosis, in search of targeted therapies, and to further characterize prognostic markers.

Entities:  

Keywords:  APC; MET; Pediatric osteosarcoma; TWIST; osteogenesis

Mesh:

Substances:

Year:  2007        PMID: 17786187      PMCID: PMC1950438          DOI: 10.1593/neo.07367

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  49 in total

Review 1.  Cbfa1: a molecular switch in osteoblast biology.

Authors:  P Ducy
Journal:  Dev Dyn       Date:  2000-12       Impact factor: 3.780

2.  Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2.

Authors:  E Zelzer; D J Glotzer; C Hartmann; D Thomas; N Fukai; S Soker; B R Olsen
Journal:  Mech Dev       Date:  2001-08       Impact factor: 1.882

3.  Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma.

Authors:  Wei-Hua Qiu; Bing-Sen Zhou; Peiguo-G Chu; Wen-Gang Chen; Christopher Chung; Jennifer Shih; Paul Hwu; Christopher Yeh; Richard Lopez; Yun Yen
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

4.  Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target.

Authors:  Wai Kei Kwok; Ming-Tat Ling; Tak-Wing Lee; Tracy C M Lau; Chun Zhou; Xiaomeng Zhang; Chee Wai Chua; Kwok W Chan; Franky L Chan; Carlotta Glackin; Yong-Chuan Wong; Xianghong Wang
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

Review 5.  Cellular and molecular interactions regulating skeletogenesis.

Authors:  Céline Colnot
Journal:  J Cell Biochem       Date:  2005-07-01       Impact factor: 4.429

6.  Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.

Authors:  J M Wood
Journal:  Medicina (B Aires)       Date:  2000       Impact factor: 0.653

7.  Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.

Authors:  Rosanne St Bernard; Lei Zheng; Wei Liu; Daniel Winer; Sylvia L Asa; Shereen Ezzat
Journal:  Endocrinology       Date:  2004-11-24       Impact factor: 4.736

8.  Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer.

Authors:  A Schneider; S Borgnat; H Lang; O Régine; V Lindner; M Kassem; C Saussine; P Oudet; D Jacqmin; M P Gaub
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

9.  Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping.

Authors:  N Entz-Werle; A Schneider; C Kalifa; A-C Voegeli; M-D Tabone; P Marec-Berard; L Marcellin; H Pacquement; P Terrier; P Boutard; N Meyer; M-P Gaub; P Lutz; A Babin; P Oudet
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Integration of FGF and TWIST in calvarial bone and suture development.

Authors:  D P Rice; T Aberg; Y Chan; Z Tang; P J Kettunen; L Pakarinen; R E Maxson; I Thesleff
Journal:  Development       Date:  2000-05       Impact factor: 6.868

View more
  21 in total

1.  Expression and significance of twist, E-cadherin, and N-cadherin in gastrointestinal stromal tumors.

Authors:  Jie Ding; Zhongmin Zhang; Yang Pan; Guoqing Liao; Liang Zeng; Senlin Chen
Journal:  Dig Dis Sci       Date:  2012-05-11       Impact factor: 3.199

2.  Targeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease.

Authors:  Natacha Entz-Werlé; Philippe Choquet; Agnès Neuville; Sabine Kuchler-Bopp; François Clauss; Jean-Marc Danse; Pauline Simo-Noumbissie; Eric Guérin; Marie-Pierre Gaub; Jean-Noel Freund; Nelly Boehm; André Constantinesco; Patrick Lutz; Dominique Guenot; Fabienne Perrin-Schmitt
Journal:  Transl Oncol       Date:  2010-12-01       Impact factor: 4.243

3.  miR-454 is down-regulated in osteosarcomas and suppresses cell proliferation and invasion by directly targeting c-Met.

Authors:  Guangfeng Niu; Bin Li; Jianmin Sun; Li Sun
Journal:  Cell Prolif       Date:  2015-04-16       Impact factor: 6.831

4.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

5.  Prognostic value of Twist and E-cadherin in patients with osteosarcoma.

Authors:  Ke Yin; Qiande Liao; Hongbo He; Da Zhong
Journal:  Med Oncol       Date:  2012-07-31       Impact factor: 3.064

6.  Plumbagin exhibits an anti-proliferative effect in human osteosarcoma cells by downregulating FHL2 and interfering with Wnt/β-catenin signalling.

Authors:  Yuan-Liang Xue; Xiang-Qi Meng; Long-Jun Ma; Zhen Yuan
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

7.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 8.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

Review 9.  Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.

Authors:  James J Morrow; Chand Khanna
Journal:  Crit Rev Oncog       Date:  2015

10.  Bone sarcomas: from biology to targeted therapies.

Authors:  Nathalie Gaspar; Angela Di Giannatale; Birgit Geoerger; Françoise Redini; Nadège Corradini; Natacha Enz-Werle; Franck Tirode; Perrine Marec-Berard; Jean-Claude Gentet; Valérie Laurence; Sophie Piperno-Neumann; Odile Oberlin; Laurence Brugieres
Journal:  Sarcoma       Date:  2012-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.